Teleflex Incorporated (TFX)
Stock Price Chart
Key Info
| Market Cap | 17.36B |
| Revenue (ttm) | 2.53B |
| Net Income (ttm) | 479.80M |
| Shares Out | 46.43M |
| EPS (ttm) | 10.16 |
| PE Ratio | 36.72 |
| Forward PE | 37.74 |
| Dividend | $1.36 |
| Dividend Yield | 0.36% |
Stock Quote
| Trading Day | Jul 31, 2020 |
| Last Price | $373.10 |
| Previous Close | $385.17 |
| Change ($) | -12.07 |
| Change (%) | -3.13% |
| Day's Open | 383.29 |
| Day's Range | 367.37 - 384.33 |
| Day's Volume | 307,815 |
| 52-Week Range | 221.27 - 405.07 |
More Stats
| Market Cap | 17.36B |
| Enterprise Value | 19.31B |
| Earnings Date (est) | Oct 29, 2020 |
| Ex-Dividend Date | May 14, 2020 |
| Shares Outstanding | 46.43M |
| Float | 46.37M |
| EPS (basic) | 10.37 |
| EPS (diluted) | 10.16 |
| FCF / Share | 7.04 |
| Dividend | $1.36 |
| Dividend Yield | 0.36% |
| Earnings Yield | 2.72% |
| FCF Yield | 1.88% |
| Payout Ratio | 13.10% |
| Shares Short | 669,850 |
| Short Ratio | 3.00 |
| Short % of Float | 1.87% |
| Beta | 1.00 |
| PE Ratio | 36.72 |
| Forward PE | 37.74 |
| P/FCF Ratio | 53.12 |
| PS Ratio | 6.87 |
| PB Ratio | 5.82 |
| Revenue | 2.53B |
| Operating Income | 440.45M |
| Net Income | 479.80M |
| Free Cash Flow | 326.72M |
| Net Cash | -1.95B |
| Net Cash / Share | -41.92 |
| Gross Margin | 59.03% |
| Operating Margin | 17.43% |
| Profit Margin | 19.00% |
| FCF Margin | 12.93% |
| ROA | 4.40% |
| ROE | 16.64% |
| ROIC | 12.70% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,595 | 2,448 | 2,146 | 1,868 | 1,810 | 1,840 | 1,696 | 1,551 | 1,493 | 1,398 |
| Revenue Growth | 6% | 14.07% | 14.9% | 3.22% | -1.64% | 8.46% | 9.37% | 3.92% | 6.78% | - |
| Gross Profit | 1,492 | 1,384 | 1,172 | 996 | 944 | 942 | 839 | 748 | 709 | 679 |
| Operating Income | 427 | 322 | 372 | 319 | 316 | 285 | 233 | -97.38 | 230 | 230 |
| Net Income | 461 | 201 | 153 | 237 | 245 | 188 | 151 | -190 | 323 | 201 |
| Shares Outstanding | 46.20 | 45.69 | 45.00 | 43.33 | 41.56 | 41.37 | 41.11 | 40.86 | 40.50 | 39.91 |
| Earnings Per Share | 9.80 | 4.29 | 3.27 | 4.98 | 5.10 | 4.04 | 3.45 | -4.65 | 7.92 | 4.99 |
| EPS Growth | 128.44% | 31.19% | -34.34% | -2.35% | 26.24% | 17.1% | - | - | 58.72% | - |
| Dividend Per Share | 1.36 | 1.36 | 1.70 | 1.36 | 1.36 | 1.36 | 1.36 | 1.36 | 1.36 | 1.36 |
| Dividend Growth | 0% | -20% | 25% | 0% | 0% | 0% | 0% | 0% | 0% | - |
| Operating Cash Flow | 440 | 437 | 420 | 408 | 301 | 287 | 228 | 187 | 94.48 | 213 |
| Capital Expenditures | -103 | -80.80 | -70.90 | -53.14 | -61.45 | -67.57 | -63.58 | -65.39 | -44.58 | -29.33 |
| Free Cash Flow | 337 | 357 | 349 | 355 | 239 | 219 | 164 | 121 | 49.90 | 184 |
| Cash & Equivalents | 301 | 357 | 334 | 544 | 338 | 303 | 432 | 337 | 584 | 208 |
| Total Debt | 2,010 | 2,159 | 2,250 | 1,033 | 1,059 | 1,068 | 1,286 | 970 | 960 | 917 |
| Net Cash / Debt | -1,709 | -1,802 | -1,916 | -490 | -721 | -765 | -854 | -633 | -376 | -709 |
| Assets | 6,310 | 6,278 | 6,181 | 3,891 | 3,872 | 3,923 | 4,209 | 3,734 | 3,924 | 3,643 |
| Liabilities | 3,331 | 3,738 | 3,751 | 1,752 | 1,861 | 2,009 | 2,293 | 1,952 | 1,941 | 1,856 |
| Book Value | 2,979 | 2,540 | 2,431 | 2,138 | 2,009 | 1,911 | 1,914 | 1,779 | 1,981 | 1,783 |
Company Profile
Company Details
| Full Name | Teleflex Incorporated |
| Country | United States |
| Employees | 14,400 |
| CEO | Liam J. Kelly |
Stock Information
| Ticker Symbol | TFX |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Unique Identifier | NYSE: TFX |
Description
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products consist of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology product comprises the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management for patients in the hospital and individuals in the home care markets. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was founded in 1943 and is headquartered in Wayne, Pennsylvania.